Hyderabad: The first batch of 2-deoxy-D-glucose (2-DG) drug for the treatment of moderate to severe Covid-19 cases will be launched next week, the Defence Research and Development Organisation has said.
The drug has been developed by the DRDO lab Institute of Nuclear Medicine and Allied Sciences in collaboration with Dr Reddy’s Laboratories.
It will be given as an adjunct therapy to Covid patients or an alternative treatment, and its purpose is to assist the primary treatment.
“The first batch of 10,000 doses of 2-DG medicine for the treatment of Covid-19 infected patients would be launched early next week and will be given to patients,” a DRDO official said.





















Discussion about this post